Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIONASDAQ:HRMYNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$39.05-2.6%$34.92$21.62▼$40.40$7.41B1.12.47 million shs2.23 million shsHRMYHarmony Biosciences$35.14-2.0%$32.04$26.47▼$41.61$2.02B0.87615,331 shs584,415 shsROIVRoivant Sciences$11.28-0.8%$10.72$8.73▼$13.06$7.67B1.165.55 million shs4.08 million shsRVMDRevolution Medicines$40.79-2.8%$38.46$29.17▼$62.40$7.60B1.11.52 million shs1.01 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-2.59%+2.71%+9.45%+20.86%+42.10%HRMYHarmony Biosciences-1.98%-0.06%-1.43%+7.40%+18.36%ROIVRoivant Sciences-0.79%+0.62%+2.64%+8.25%+6.72%RVMDRevolution Medicines-2.83%+1.02%-2.60%+4.51%+4.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.6239 of 5 stars4.52.00.03.92.73.30.6HRMYHarmony Biosciences4.7766 of 5 stars4.61.00.00.03.43.34.4ROIVRoivant Sciences2.3781 of 5 stars3.53.00.00.01.92.50.0RVMDRevolution Medicines4.4448 of 5 stars4.51.00.04.73.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$57.3646.90% UpsideHRMYHarmony Biosciences 3.11Buy$53.0050.83% UpsideROIVRoivant Sciences 3.00Buy$17.5055.14% UpsideRVMDRevolution Medicines 3.00Buy$67.0864.46% UpsideCurrent Analyst Ratings BreakdownLatest HRMY, ROIV, RVMD, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$53.00 ➝ $56.006/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.005/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$127.42M58.19N/AN/A($7.71) per share-5.06HRMYHarmony Biosciences$744.85M2.71$2.63 per share13.38$7.97 per share4.41ROIVRoivant Sciences$29.05M263.94N/AN/A$7.76 per share1.45RVMDRevolution Medicines$742K10,239.72N/AN/A$11.09 per share3.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%7/30/2025 (Estimated)HRMYHarmony Biosciences$128.85M$2.6216.6511.300.4717.98%23.16%14.24%8/5/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.25N/AN/AN/A-119.54%-14.05%-12.81%8/6/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)Latest HRMY, ROIV, RVMD, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.674.67HRMYHarmony Biosciences0.283.243.20ROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%HRMYHarmony Biosciences86.23%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%HRMYHarmony Biosciences23.60%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million143.29 millionOptionableHRMYHarmony Biosciences20057.42 million39.47 millionOptionableROIVRoivant Sciences860679.81 million657.18 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableHRMY, ROIV, RVMD, and BBIO HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. (NASDAQ:RVMD) Receives $67.08 Average Price Target from BrokeragesJune 4, 2025 | americanbankingnews.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)June 1, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from AnalystsJune 1, 2025 | marketbeat.com22,725 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Jefferies Financial Group Inc.May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Has $2.09 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 30, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Up 3.9% - Should You Buy?May 29, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's WhyMay 28, 2025 | marketbeat.comPolar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 28, 2025 | marketbeat.comRevolution Medicines’ SWOT analysis: stock shows promise amid clinical progressMay 27, 2025 | investing.comNuveen Asset Management LLC Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 26, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 26, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by ProShare Advisors LLCMay 23, 2025 | marketbeat.comBank of America Corp DE Has $17.54 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 23, 2025 | marketbeat.comWoodline Partners LP Has $169.96 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Sells 503,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 21, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.May 21, 2025 | marketbeat.comRevolution Medicines Inc.May 20, 2025 | wsj.comTang Capital Management LLC Invests $4.37 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comTema Etfs LLC Invests $1.99 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comMan Group plc Buys 65,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comDeutsche Bank AG Has $7.76 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRMY, ROIV, RVMD, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$39.05 -1.04 (-2.59%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$39.05 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Harmony Biosciences NASDAQ:HRMY$35.14 -0.71 (-1.98%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$35.15 +0.01 (+0.03%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Roivant Sciences NASDAQ:ROIV$11.28 -0.09 (-0.79%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$11.29 +0.01 (+0.08%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$40.79 -1.19 (-2.83%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$40.79 0.00 (0.00%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal The Other AI Chipmaker: Why Marvell's Dip Is a Buy Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
